Paco Cifuentes

Paco Cifuentes is currently a Venture Partner at Genoa Ventures, an early-stage venture capital firm focused on the convergence of biology and technology. In this role, he helps manage strategic investments from the firm's second flagship vehicle, Genoa Ventures Fund II, which successfully closed with $84 million in capital commitments in July 2022. His investment mandate targets early-stage startups operating across the broader life sciences sector, specifically evaluating new venture opportunities in research tools, clinical diagnostics, agricultural technology, and industrial biotechnology. Cifuentes supports a portfolio that has generated notable liquidity events, including the 2021 acquisition of analytical instrument developer Intabio by the global life sciences company SCIEX. Holding a Ph.D., his current professional focus remains on leveraging his technical expertise to identify and scale emerging companies at the intersection of biological sciences and advanced technology.